FDA Grants Fast Track Status to Immunotherapy Candidate TRQ-1501 for Some Solid Tumors, Lymphomas .

TRQ-1501, an experimental immune cell cancer therapy developed by Torque, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of certain hard-to-treat solid tumors and lymphomas.

The designation is given to therapies that show potential to treat serious health conditions, and is intended to accelerate their development and approval by providing more frequent meetings and discussions with the FDA.

“Patients with relapsed or refractory solid tumors and lymphomas have a poor prognosis and limited treatment options. We are delighted to receive this Fast Track designation of TRQ-1501 for a broad, tumor-agnostic indication, which provides significant flexibility for our clinical trial program,” Becker Hewes, MD, chief medical officer of Torque, said in a press release. ...